Choreo LLC Buys Shares of 1,441 Medpace Holdings, Inc. $MEDP

Choreo LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, Holdings Channel reports. The firm purchased 1,441 shares of the company’s stock, valued at approximately $452,000.

A number of other large investors also recently modified their holdings of MEDP. Portside Wealth Group LLC grew its position in Medpace by 2.5% during the 2nd quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after acquiring an additional 27 shares during the last quarter. PDS Planning Inc grew its holdings in shares of Medpace by 1.5% during the second quarter. PDS Planning Inc now owns 2,421 shares of the company’s stock worth $760,000 after purchasing an additional 35 shares during the last quarter. Benjamin Edwards Inc. raised its holdings in Medpace by 3.1% in the 1st quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company’s stock valued at $366,000 after buying an additional 36 shares during the last quarter. Geneos Wealth Management Inc. boosted its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Finally, Sheets Smith Wealth Management boosted its position in Medpace by 1.3% during the 2nd quarter. Sheets Smith Wealth Management now owns 3,332 shares of the company’s stock worth $1,046,000 after buying an additional 43 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 1.2%

MEDP stock opened at $576.49 on Thursday. The firm has a market cap of $16.24 billion, a price-to-earnings ratio of 40.31, a PEG ratio of 2.21 and a beta of 1.43. The company’s fifty day simple moving average is $565.74 and its 200 day simple moving average is $450.35. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $626.26.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period last year, the company posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on MEDP shares. Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Jefferies Financial Group increased their price objective on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a report on Tuesday, September 9th. Rothschild & Co Redburn lowered Medpace from a “buy” rating to a “neutral” rating and raised their target price for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. TD Cowen upped their price target on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research report on Friday, October 24th. Finally, Robert W. Baird set a $613.00 price target on Medpace in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat, Medpace has a consensus rating of “Hold” and an average price target of $487.18.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the sale, the vice president owned 27,500 shares in the company, valued at $16,751,625. The trade was a 42.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Kevin M. Brady sold 3,000 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the transaction, the chief financial officer owned 6,000 shares in the company, valued at $3,542,100. The trade was a 33.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 387,257 shares of company stock worth $232,992,066. 20.30% of the stock is owned by corporate insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.